In a patient with coronary artery disease who has received a drug‑eluting stent, how long should ticagrelor (Brilinta) be continued?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Duration of Ticagrelor (Brilinta) After Drug-Eluting Stent in CAD

For patients with coronary artery disease who received drug-eluting stents for acute coronary syndrome, ticagrelor should be continued for at least 12 months; for stable coronary disease, at least 6 months is required. 1, 2, 3

Standard Duration Based on Clinical Presentation

Acute Coronary Syndrome (ACS)

  • Ticagrelor 90 mg twice daily must be continued for a minimum of 12 months after DES implantation 1, 2, 3
  • This 12-month recommendation applies regardless of stent type (bare metal or drug-eluting) 1, 2
  • Ticagrelor is preferred over clopidogrel for maintenance therapy in ACS patients 1, 2, 3
  • Aspirin 81 mg daily (range 75-100 mg) should be continued alongside ticagrelor 1, 2, 3

Stable Ischemic Heart Disease (SIHD)

  • Minimum duration is 6 months after DES implantation 2, 3
  • Some guidelines suggest 1-6 months depending on bleeding risk, with 6 months being standard for patients without high bleeding risk 4, 5
  • Aspirin 81 mg daily should be maintained indefinitely 2, 3

Extension Beyond Standard Duration

When to Consider Prolonged Therapy (>12 months)

Continuation beyond 12 months may be reasonable if ALL of the following criteria are met: 1, 2, 3, 6

  • Patient has tolerated DAPT without any bleeding complications during the initial 12 months
  • Patient is NOT at high bleeding risk (no prior bleeding on DAPT, no coagulopathy, no oral anticoagulant use)
  • Patient has not experienced significant overt bleeding

For extended therapy beyond 12 months, consider reducing ticagrelor dose to 60 mg twice daily (not 90 mg) for long-term secondary prevention 6

High-Risk Features Favoring Extended Therapy

Patients with complex coronary disease may benefit from prolonged DAPT: 6

  • Multivessel disease including left main involvement
  • Prior myocardial infarction
  • Chronic kidney disease
  • History of stent thrombosis
  • Complex PCI (multivessel stenting, >30 mm stent length, bifurcation lesions)

Early Discontinuation Scenarios

ACS Patients with High Bleeding Risk

Discontinuation after 6 months may be reasonable if: 1, 2, 3

  • Patient develops high bleeding risk (e.g., requires oral anticoagulation therapy)
  • Patient is at high risk of severe bleeding complications (e.g., major intracranial surgery planned)
  • Patient develops significant overt bleeding

SIHD Patients with High Bleeding Risk

Discontinuation after 3 months may be reasonable if: 2, 3

  • Patient develops treatment indication requiring oral anticoagulation
  • Patient faces high risk of severe bleeding complications
  • Significant overt bleeding occurs

General Principle for Early Discontinuation

If the morbidity risk from bleeding clearly outweighs the anticipated ischemic benefit, earlier discontinuation is reasonable 1, 2, 7

Critical Management Points

Aspirin Dosing

  • Use 81 mg daily (acceptable range 75-100 mg) when combined with ticagrelor 1, 2, 8, 3
  • Higher aspirin doses increase bleeding without improving efficacy 8, 6
  • Aspirin should be continued indefinitely after stopping ticagrelor 8, 6

If CABG is Required

  • Stop ticagrelor at least 3 days before elective CABG 4, 6
  • Resume ticagrelor as soon as possible after CABG to complete the 12-month course in ACS patients 1, 2, 6
  • Aspirin should be continued throughout the perioperative period 4

Common Pitfalls to Avoid

Do not stop ticagrelor before 12 months in ACS patients without compelling bleeding reasons - this dramatically increases thrombotic risk including stent thrombosis 1, 2, 3, 6

Do not use ticagrelor 90 mg twice daily for therapy extending beyond 12 months - the approved dose for long-term secondary prevention is 60 mg twice daily 6

Do not discontinue therapy without discussing with the interventional cardiologist - premature cessation is a leading cause of stent thrombosis 3

Do not use aspirin doses >100 mg daily with ticagrelor - this increases bleeding without additional benefit 8, 6

Do not abruptly stop aspirin after discontinuing ticagrelor - aspirin monotherapy should continue for life 8, 6

Do not prescribe prasugrel instead of ticagrelor if the patient has prior stroke or TIA - prasugrel is contraindicated in these patients 1, 2, 7, 6

References

Guideline

Ticagrelor Therapy Duration After Drug-Eluting Stent Placement

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

acc/aha versus esc guidelines on dual antiplatelet therapy: jacc guideline comparison.

Journal of the American College of Cardiology, 2018

Guideline

Duration of Dual Antiplatelet Therapy After Stent in Acute Myocardial Infarction

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.